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To quantify the full range of tryptophan metabolites along the kynurenine pathway, a liquid chroma-
tography e tandem mass spectrometry method was developed and used to analyse brain extracts of
rodents treated with the kynurenine-3-mono-oxygenase (KMO) inhibitor Ro61-8048 during pregnancy.
There were signiﬁcant increases in the levels of kynurenine, kynurenic acid, anthranilic acid and 3-
hydroxy-kynurenine (3-HK) in the maternal brain after 5 h but not 24 h, while the embryos exhibited
high levels of kynurenine, kynurenic acid and anthranilic acid after 5 h which were maintained at 24 h
post-treatment. At 24 h there was also a strong trend to an increase in quinolinic acid levels (P ¼ 0.055).
No signiﬁcant changes were observed in any of the other kynurenine metabolites. The results conﬁrm the
marked increase in the accumulation of some neuroactive kynurenines when KMO is inhibited, and re-
emphasise the potential importance of changes in anthranilic acid. The prolonged duration of metabolite
accumulation in the embryo brains indicates a trapping of compounds within the embryonic CNS
independently of maternal levels. When brains were examined from young mice heterozygous for the
meCP2 gene e a potential model for Rett syndrome - no differences were noted from control mice,
suggesting that the proposed roles for kynurenines in autism spectrum disorder are not relevant to Rett
syndrome, supporting its recognition as a distinct, independent, condition.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The kynurenine pathway is the major route for tryptophan
metabolism, oxidising around 95% of free tryptophan to several
compounds with biological activity at glutamate receptors, such as
quinolinic acid (Stone and Perkins, 1981; Stone and Darlington,
2002) and kynurenic acid (Perkins and Stone, 1982). Both these
compounds have important actions on the N-methyl-D-aspartate
(NMDA) sensitive population of receptors for glutamate at which
quinolinic acid is an agonist and kynurenic acid is an antagonist,iversity of Glasgow, Glasgow,
Stone).
Ltd. This is an open access articleacting at the glycine/D-serine site of NMDA receptors (Birch et al.,
1988).
Concentrations of kynurenate are altered in the brains of pa-
tients with disorders such as schizophrenia (Nilsson et al., 2005;
Schwarcz. et al., 2001; see Stone and Darlington, 2013) and there
is strong evidence for a role also in Huntington's disease (Forrest
et al., 2010; Schwarcz et al., 2009). Both of these disorders
involve abnormalities in brain development or maturation and
NMDA receptors are intimately involved in the early formation of
the embryonic brain (Iwasato et al., 2000; Ramoa et al., 2001),
where they inﬂuence progenitor migration, axon guidance, contact
formation, dendritic and spine formation (Alvarez et al., 2007;
Colonnese et al., 2005; Rajan and Cline, 1998; Ultanir et al., 2007).
Increasing the endogenous concentration of kynurenic acid in theunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Attempts to clarify the mechanisms by which the kynurenine
pathway inﬂuences these aspects of brain function have involved
inducing changes in the brain concentrations of kynurenines by the
administration of kynurenine (Chess et al., 2007; Pocivavsek et al.,
2012), pharmacological inhibition of the key kynurenine metabolic
enzyme kynurenine-3-mono-oxygenase (KMO) (Forrest et al.,
2013a,b; Khalil et al., 2014) or deletion of the gene for this
enzyme inmice (Giorgini et al., 2013). Inhibition or deletion of KMO
blocks the oxidation of kynurenine to 3-hydroxy-kynurenine,
providing a higher concentration of kynurenine as a substrate for
kynurenine aminotransferase, which metabolises it to kynurenic
acid. These procedures have demonstrated that during early brain
formation, in utero, an inhibitor of KMO produces changes in the
morphological, biochemical and electrophysiological development
of the brains of the offspring (Forrest et al., 2013a,b; Khalil et al.,
2014; Pisar et al., 2014), indicating that activity along the kynur-
enine pathway is actively involved in early brain formation and its
subsequent maturation.
As part of these latter studies, tissue samples were analysed by
HPLC to determine the levels of tryptophan and its major metab-
olites in the embryonic and maternal brain 5 h and 24 h after the
administration of the KMO inhibitor Ro61-8048 (Forrest et al.,
2013a). However, samples of brain were also retained from the
animals used in those studies with the aim of developing a highly
sensitive mass spectrometry assay with which to examine changes
simultaneously in the levels of all of the major kynurenine me-
tabolites. This report presents the new data on brain levels of
tryptophan, kynurenine, kynurenic acid, quinolinic acid, anthranilic
acid, xanthurenic acid and 3-hydroxykynurenine, which support
and extend our earlier observations. The question being addressed
in the ﬁrst part of the study is how KMO inhibition during gestation
affects kynurenine metabolism in the maternal and embryonic
brain and whether changes in the embryo could underlie the
emergence of behavioural disorders postnatally.
In additionwe have applied the new analysis system to examine
kynurenine metabolites in the brains of female mice heterozygous
for the X-linked Mecp2 gene. Deletion of this gene has been
considered to represent an accurate genetic model of Rett syn-
drome, a neurodevelopmental disorder affecting females and
characterised by motor, cognitive and autonomic impairment as
well as autistic features during a childhood regression phase (Chen
et al., 2001; Guy et al., 2001). Riederer et al. (1986) reported
increased levels of kynurenine in post-mortem brain tissue of pa-
tients suffering from Rett syndrome but, to our knowledge, no
measurements have been made of the full complement of trypto-
phan metabolites in an animal model of the disorder. The question
being addressed here is whether any changes in kynurenine
metabolism can be identiﬁed in a mouse model of Rett syndrome.
2. Materials and methods
The use of animals has been described in the original studies
from which the present brain samples were taken (Forrest et al.,
2013a,b; 2015). The work was carried out according to the regula-
tions of the Animals (Scientiﬁc Procedures) act 1986 of the UK,
administered and monitored by the Home Ofﬁce. Brieﬂy, pregnant
female Wistar rats were housed alone with free access to food and
water. Kynurenine oxidation to 3-hydroxy-kynurenine (3-HK) was
blocked by 3,4-dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]ben-
zenesulphonamide (Ro61-8048) (R€over et al., 1997) which inhibits
kynurenine-3-mono-oxygenase (KMO) and shifts the catabolism of
kynurenine away from 3-HK and towards the NMDA receptor
antagonist, kynurenic acid (Cozzi et al., 1999; Clark et al., 2005;
Forrest et al., 2013a,b). A dose of 100 mg/kg (i.p.) was identiﬁedas one suitable for repeated administration to rodents (Clark et al.,
2005; Rodgers et al., 2009) and this was injected to the pregnant
rats on days E14, E16 and E 18 of pregnancy. Control animals were
injected with the saline vehicle. Two time points were selected for
analysis of the brains, 5 h and 24 h after the ﬁnal administration of
Ro61-8048, at which times the animals were killed by an overdose
of anaesthetic (25% w/v urethane inwater, 2.5 g/kg i.p.) followed by
cervical dislocation.
Female Mecp2þ/ mice and the wild type litternate controls
were used. The Mecp2tm1.1Bird mice were originally provided as a
kind gift from Professor Adrian Bird (University of Edinburgh) and
maintained on a C57BL/6 background. Animals weremaintained on
12-h light/dark cycles with free access to normal mouse food. Mice
were genotyped as described previously (Guy et al., 2001).
2.1. Brain sample extraction
Samples were kept on ice throughout the extraction procedure.
Mouse brains were prepared by homogenising in 5 vols (wt/vol) of
HPLC grade methanol. Samples were homogenised for 30 s using a
polytron (Fisher Scientiﬁc, Loughborough, UK) then centrifuged at
10,000 g for 10 min at 4 C. The supernatants were collected and
ﬁltered in MicroSpin PVDF centrifuge tubes (Alltech, Carnforth,
Lancashire, UK) using centrifugation at 10,000 g for 5 min at 4 C.
The ﬁltrates were stored at 80 C until mass spectrometric
analysis.
2.2. Brain sample preparation
For the measurement of tryptophan and kynurenine, 10 ml of
blank (deionised water), aqueous standards, and ﬁltered brain ex-
tracts were mixed with 150 ml of stable isotope mix in methanol
(5 ml 10 mM 2H5-tryptophan and 5 ml 0.64 mM 2H6-kynurenine
sulphate in 20 ml methanol), vortex mixed and centrifuged for
5 min at 21,000g.
For the measurement of kynurenic acid, anthranilic acid, 3-
hydroxykynurenine, 3-hydroxyanthranilic acid, xanthurenic acid,
quinolinic acid, and picolinic acid, 150 ml of blank (deionised water),
aqueous standards, and ﬁltered brain extracts were mixed with
15 ml of the stable isotope mix in methanol (1:1:1, 2 mM 2H5-
kynurenic acid, 5 mM 13C3,15N-quinolinic acid, 40 mM 2H3-picolinic
acid), vortex mixed and centrifuged for 5 min at 21,000g. Super-
natants were transferred to a 96-deep well polypropylene plate,
sealing mat applied, and the plate placed in the autosampler cooled
to 7.5 C, awaiting injection.
2.3. Kynurenine metabolite analysis
Several groups have established the value of analytical systems
based on mass spectrometry for components of the kynurenine
pathway which represents the main route for the oxidation of
tryptophan (Marcos et al., 2016; Galba et al., 2016; Orsatti et al.,
2015; Schwieler et al., 2015; Savitz et al., 2015; Zhang et al., 2015;
Meinitzer et al., 2014; Lesniak et al., 2013; Zheng et al., 2012;
Moller et al., 2012; Wilson et al., 2012; Notarangelo et al., 2012;
Owe-Young et al., 2008; Amirkhani et al., 2002; Boni et al., 1994;
Smythe et al., 2002; Kita et al., 2002; Saito et al., 1993). These
systems have been applied to the measurement of individual
kynurenines in blood, plasma or cerebrospinal ﬂuid as well as
components of the kynurenine pathway within brain tissue. In the
present work, tryptophan, kynurenine, and kynureninemetabolites
were measured by liquid chromatography-tandem mass spec-
trometry using a CTC PAL HTS-XT, Agilent 1260 Inﬁnity liquid
chromatograph, and AB SCIEX 6500 QTRAP mass spectrometer (AB
Sciex UK Ltd,Warrington, UK). All results were calculated in Analyst
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Analytical chemicals and reagents: Tryptophan, kynurenine,
kynurenic acid, anthranilic acid, 3-hydroxykynurenine, 3-
hydroxyanthranilic acid, xanthurenic acid, picolinic acid and qui-
nolinic acid were obtained from Sigma Aldrich, Poole, Dorset UK.
The stable isotope labelled internal standards were: 2H5-trypto-
phan (QMx Laboratories, Thaxted, UK), 2H6-kynurenine sulphate
and 2H5-kynurenic acid (CK isotopes, Ibstock, UK), and 2H3-pico-
linic acid and 13C3,15N-quinolinic acid (LGC standards, Teddington,
UK). Acetonitrile and methanol were obtained from Rathburn
Chemicals Ltd., Walkerburn, UK and Fisher Scientiﬁc UK Ltd,
Loughborough, UK, respectively.
2.3.1. Analyte tuning and MRM optimisation
Standards of each analyte were used to automatically tune in
multiple reaction monitoring (MRM) mode. Transition optimisa-
tions were performed manually. Xanthurenic acid was signiﬁcantly
more sensitive in negative ion mode but, with the chromatographic
conditions used, there was massive matrix ion suppression.
Consequently, xanthurenic acid was measured in positive ion
mode.
2.3.2. Liquid chromatography-tandem mass spectrometry
Analyte retention times on Chirobiotic-T columns tend to be
matrix dependent, hence the critical requirement for the appro-
priate stable isotope internal standards. Consequently, where stable
isotopes were unavailable, two separate transitions, where
possible, were used to calculate and then conﬁrm the result.
2.3.3. Positive ion MRM mode acquisitions
Isocratic chromatography of tryptophan and kynurenine (5 ml
injection volume; data acquisition time 6 min), and kynurenic acid,
anthranilic acid, 3-hydroxykynurenine, 3-hydroxyanthranilic acid,
and xanthurenic acid (10 ml injection volume; data acquisition time
7 min) was performed on a 5 mm ASTEC Chirobiotic eT,
10 cm  2.1 mm i.d. column and guard column, using 1:1 aceto-
nitrile/water with 0.025% formic acid at a ﬂow rate of 200 ml/min.
MSMS parameters: Curtain Gas: 40, CAD Gas: medium, Ion Source
voltage: 5250 V, Gas temperature: 400 C, Gas 1: 25, Gas 2: 25.
2.3.4. Negative ion MRM mode acquisitions
Isocratic chromatography of quinolinic acid and picolinic acid
(10 ml injection volume; data acquisition time 4 min) was per-
formed on a 5 mmASTEC ChirobioticeT,10 cm 2.1mm i.d. column
and guard column, using 62.5% water/acetonitrile at a ﬂow rate of
225 ml/min. MSMS parameters: Curtain Gas: 45, CAD Gas: medium,
Ion Source voltage: 4500 V, Gas temperature: 400 C, Gas 1: 30,
Gas 2: 30 (see Table 1).
2.4. Data analysis and statistics
All data are expressed as the mean ± 1 S.E.M with n values cited
in the text of Figure legends. Statistical comparisons were per-
formed using two-tailed t tests between two sets of data or ANOVA
followed by Dunnet's test for comparing datasets to a single control
set, or the Bonferroni test using selected datasets when multiple
comparisons were required. A probability value of P  0.05 was
used as the criterion for statistical signiﬁcance.
2.5. Sources of compounds
Sources of the compounds used for analysis are listed above in
section 2.3. The KMO inhibitor Ro61-8048 was partly obtained as a
gift from Dr. S. Roever, F. Hoffmann-La Roche Ltd., Basel,
Switzerland, and partly purchased from Tocris chemicals (Bristol,UK).
3. Results
3.1. Ro61-8048 treatment
In the adult pregnant female, the administration of Ro61-8048
produced substantial and highly signiﬁcant increases in the con-
centrations of the main kynurenine metabolites of tryptophan in
the rat brain. Tryptophan itself showed no change after 5 h or 24 h,
whereas kynurenine, 3-HK and kynurenic acid showed substan-
tially increased levels after 5 h (Fig. 1). However, by 24 h following
Ro61-8048 there were no signiﬁcant differences between the
control and treated animals (Fig. 2). Therewas also a signiﬁcant rise
in the concentration of anthranilic acid after 5 h which was no
longer signiﬁcant after 24 h partly due to a high variance (Fig 2).
There was a strong trend for xanthurenic acid to be decreased by
approximately 50% after 24 h but this was not signiﬁcant (Fig. 2).
Quinolinic acid levels did not change at either time point.
In the embryos, there were also highly signiﬁcant increases in
the concentrations of kynurenine, kynurenic acid and anthranilic
acid at 5 h (Fig. 3), but these remained high, with little diminution
at 24 h from the earlier levels (Fig. 4) in contrast to the adult data.
There were no changes in the concentrations of 3-HK, xanthurenic
acid or quinolinic acid at either time point.
The controls levels of kynurenine and kynurenic acid at 24 h are
comparable in the adults (Fig. 2) and embryos (Fig. 4). The
increased levels produced by Ro61-8048, however, remain around
10 times the control levels in the embryos (Fig. 4) whereas levels
have returned to approximately normal in the adults (Fig. 2). There
is a tendency for the levels of kynurenine and kynurenic acid to be
lower in the adults at 5 h (Fig. 1) than at 24 h (Fig. 2). Since all the
animals in this study were in the late stages of gestation, the dif-
ference may be related to the trauma of handling and injection,
procedures which could have transiently depressed tryptophan
metabolism for up to 5 h, returning towards normal by 24 h.
Concentrations of anthranilic acid were similar in the adult and
embryo brains (around 50 pmol s/g. wet weight), but 3-HK levels
were signiﬁcantly higher in the embryos at 5 h (66.8 ± 12.6 pmol/g
wet weight) and 24 h (65.68 ± 4.1 pmol/g wet weight) than in the
maternal brains (18.65 ± 2.51, P ¼ 0.02 and 30.35 ± 4.9 pmol/g wet
weight, P ¼ 0.005 respectively).
Interestingly, given the lack of effect of Ro61-8048 on overall
levels of quinolinic acid, the concentration of this compound is
around 6 times higher in embryo brains (Figs. 3 and 4) compared
with maternal brain (Figs. 1 and 2).
3.2. Mecp2þ/ mice
In the brain samples from female mice (3e6 weeks old) mosaic
for MeCP2 expression (lacking functional MeCP2 in ~50% of brain
cells as occurs in patients with Rett syndrome), no differences were
detected in any of the metabolites examined including tryptophan,
kynurenine, kynurenic acid, xanthurenic acid and quinolinic acid,
all of which were completely unchanged compared with wild-type
littermate control animals (Fig. 5). There was a tendency for
anthranilate levels to be reduced in the mutants, but this did not
achieve signiﬁcance.
3.2.1. Comparison of mouse and rat data
Although few direct comparisons have been made of all the
brain tryptophan metabolite levels in rat and mouse brains, it was
interesting to note that the basal levels of tryptophan (~35 nmol/
g.wet wt), kynurenine (~0.4 nmol/g.wet wt), xanthurenic acid
(~12 pmol/g.wet wt), anthranilic acid (~40 pmol/g.wet wt) and
Table 1
Values for ion MRM mode acquisitions.
m/z DP EP CE CXP ST1
Positive ion MRM mode acquisitions:
Tryptophan 205.16/146.00 6 10 25 10 13
2H5-tryptophan 210.16/151.00 6 10 25 10 13
Kynurenine 209.10/94.10 71 10 21 12 13
2H6-kynurenine 215.10/98.10 71 10 21 12 13
Kynurenic acid 189.93/144.00 46 10 30 12 13
2H5-kynurenic acid 194.93/149.00 46 10 30 12 13
Anthranilic acid 138.20/92.00 41 10 29 12 13
Anthranilic acid, conﬁrmation 138.20/120.20 41 10 15 10 13
3-hydroxykynurenine 225.10/110.10 61 10 23 14 13
3-hydroxykynurenine, conﬁrmation 225.10/208.20 33 10 14 10 13
3-hydroxyanthranilic acid 154.10/80.10 35 10 36 15 13
Xanthurenic acid 206.00/160.00 45 10 44 12 13
Negative ion MRM mode acquisitions:
Quinolinic acid 166.044/122.100 30 10 14 9 13
13C3,15N-quinolinic acid 170.044/126.100 30 10 14 9 13
Picolinic acid 121.989/77.800 120 10 16 31 13
2H3-picolinic acid 124.880/81.000 30 10 15 10 13
Abbreviations: Declustering Potential (DP), Entrance Potential (EP), Collision Energy (CE), Exit Potential (CXP), Preﬁlter (ST1).
Fig. 1. Tryptophan metabolism in adult female rat brains. The charts summarise the concentrations of (A) tryptophan, (B) kynurenine, (C) kynurenic acid, (D) 3-hydroxykynurenine,
(E) xanthurenic acid, (F) anthranilic acid and (G) quinolinic acid in the brains of pregnant female rats 5 h after the intraperitoneal administration of Ro61-8048. *P < 0.05; **P < 0.01;
***P < 0.001 (paired t-test, n ¼ 3).
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and the untreated adult female rat controls described above. These
values are also comparable with the baseline levels reported in
previous studies (Tenorio-Lopez et al., 2007). The levels of kynur-
enic acid in mice, however, were only around 12% of those seen in
rats (~3 and ~25 pmol/g.wet wt respectively) whereas the 3-HK
levels were approximately 4-fold higher in the mice (~80 pmol/
g.wet wt) compared with the rat brains (~20 pmol/g.wet wt).
Compared with the embryonic rat brain, concentrations oftryptophan, kynurenine, kynurenic acid and quinolinic acid in the
mouse brains were signiﬁcantly lower, with kynurenic acid and
quinolinic acid being of the order of 10-fold less in the mice.
Giorgini et al. (2013) employed the same background mouse
strain (C57BL/6J) for the original conditional knockouts of KMO as
were used for the meCP2 knockout animals, although the KMO(/
) animals were then back-crossed into an FVBN background.
Nevertheless it was reassuring to note that the levels of tryptophan
(~30 nmol/g.wet wt), kynurenic acid (~2.5 pmol/g.wet wt) and
Fig. 2. Tryptophan metabolism in adult female rat brains. The charts summarise the concentrations of (A) tryptophan, (B) kynurenine, (C) kynurenic acid, (D) 3-hydroxykynurenine,
(E) xanthurenic acid, (F) anthranilic acid and (G) quinolinic acid in the brains of pregnant female rats 24 h after the intraperitoneal administration of Ro61-8048, a time at which
there were no longer any signiﬁcant differences (paired t-test, n ¼ 3).
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wild type animals in the two studies. However, kynurenine levels
were around 10-fold less in the present study and anthranilic acid
levels were 10-fold higher.4. Discussion
The importance of understanding the manner in which kynur-
enic acid and quinolinic acid production are regulated lies in the
recognition that their modulation of NMDA receptor function may
be relevant to several CNS disorders. These include Huntington's
disease (Forrest et al., 2010; Schwarcz et al., 2009) schizophrenia
(Schwarcz. et al., 2001; Nilsson et al., 2005; see Stone and
Darlington, 2013) as well as ASD. Strong arguments have been
advanced that these latter two conditions may be related to envi-
ronmental inﬂuences on the early development of the brain in utero
(Casanova, 2007). Given the actions of quinolinic acid as an NMDA
receptor agonist and kynurenic acid as an antagonist, and that their
concentrations are altered by infection (via interferon induction of
cellular indoleamine-2,3-dioxygenase, IDO) and stress (via the
corticosteroid induction of hepatic tryptophan-2,3-dioxygenase,
TDO), it is reasonable to consider the possibility that changes in
kynurenine metabolism could be involved.
The present results are broadly in agreement with data obtained
using HPLC for kynurenine and kynurenic acid concentrations
following KMO inhibition (Forrest et al., 2013a), which revealed
large changes obtained 5 h after Ro61-8048 but which were
restored to control levels after 24 h in the adult maternal brain
while remaining elevated in the embryos. Increased synthesis of
kynurenic acid has also been observed after Ro61-8048 treatmentof mice in a study of the effects of cerebral malaria (Clark et al.,
2005). In that study, kynurenate concentrations in the brain were
increased up to 100-fold, while there was little change in the
concentrations of quinolinic acid, again supporting the proﬁle of
metabolism obtained here.
The ability of tryptophan metabolism to change to this extent in
the formation of kynurenine and kynurenic acid without any sig-
niﬁcant alteration in quinolinic acid synthesis remains unex-
plained. It has been proposed that the conversion of anthranilic acid
to quinolinic acid could account for the observation, assuming that
the quinolinate synthase activity necessary (Baran and Schwarcz,
1990) is regulated quite precisely in order to compensate for the
loss of quinolinic acid normally generated from kynurenine via 3-
HK. However, in the present analysis, concentrations of 3-HK
were themselves elevated after 5 h in the adult brain, in parallel
with the change in anthranilate levels, while quinolinic acid con-
centrations remained normal. Although it has not been demon-
strated experimentally, it may be that there is a degree of inter-
conversion between anthranilate and 3-HK which together are
responsible for maintaining quinolinic acid synthesis in order to
protect the generation of nicotinamide and nicotinamide adenine
dinucleotide (NAD). It is unfortunate that the present analysis was
unable to quantify the levels of 3-hydroxy-anthranilic acid, which is
known to change in the opposite direction to anthranilate in some
conditions, such as the presence of inﬂammation (Darlington et al.,
2010).
It remains unclear whether Ro61-8048 is acting directly on this
embryonic pathway. The blood-brain barrier is not fully functional
until after birth, so that Ro61-8048 is likely to penetrate the em-
bryonic brain far more readily than the maternal brain, resulting in
Fig. 3. Tryptophan metabolism in embryo rat brains. The charts summarise the concentrations of (A) tryptophan, (B) kynurenine, (C) kynurenic acid, (D) 3-hydroxykynurenine, (E)
xanthurenic acid, (F) anthranilic acid and (G) quinolinic acid in the brains of rat embryos 5 h after the intraperitoneal administration of Ro61-8048 to the mother. ***P < 0.001
(paired t-test, n ¼ 6).
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inhibition should not affect the overall results. Whether inhibition
occurs within the embryo brain, within the maternal circulation or
within the maternal brain, the consequence of enzyme inhibition
should be, primarily, to increase the tissue levels of kynurenine.
Since kynurenine is able to cross the placental and blood-brain
barriers relatively easily, it should then lead to raised levels of
kynurenic acid in all these tissues. The main uncertainty is that, in
tissues where Ro61-8048 is present in very low concentration,
kynurenine will still be converted to 3-HK and quinolinic acid at
normal rates, rather than subnormal rates in the presence of KMO
inhibition, so that the ratio of kynurenic acid to quinolinic acid may
depend to some extent on Ro61-8048 penetration. This is poten-
tially an important issue since it is the ratio between the levels of
kynurenic acid (as a glutamate antagonist and neuroprotectant)
and quinolinic acid (an NMDA receptor agonist and excitotoxin)
that will determine the overall results of kynurenine pathway ac-
tivity. The problem is likely to be moderated, however, by the fact
that 3-HK, like kynurenine itself, can pass the placental and blood-
brain barriers, thus compensating for any lack of tissue penetration
by Ro61-8048.
However, the kynurenine proﬁle seen here is not unique to the
administration of a synthetic chemical (Ro61-8048). The deletion of
the kmo gene in mice has been reported to yield a similar proﬁle of
tryptophan metabolism to that observed here, with substantially
increased levels of kynurenine, kynurenic acid and anthranilic acid
in the brain but relatively little change (approximately 20%, albeit
statistically signiﬁcant) in the presence of quinolinic acid (Giorgini
et al., 2013). That knockdown study did, however, include mea-
surements of metabolite levels in the plasma and liver, both ofwhich did exhibit a signiﬁcant decrease in quinolinic acid produc-
tion. The constancy of quinolinate levels in the brainmay, therefore,
reﬂect the limited passage of ionised compounds across the blood-
brain barrier, resulting in the entrapment of quinolinic acid within
the tissue. This would support the growing belief that quinolinate
concentrations should be regulated within strict limits within the
brain if levels are not to be reached which would be neurotoxic
(Guillemin, 2012; Guillemin et al., 2005; Stone et al., 2012).4.1. Neurodevelopment
The ability of KMO inhibition to alter brain development sup-
ports the concept that the kynurenine pathway plays a key role in
the early development of the CNS. The pathway is certainly present
in the embryonic brain (Beal et al., 1992; Cannazza et al., 2001;
Guillemin et al., 2001, 2005; Schwarcz and Pellicciari, 2002;
Walker et al., 1999), with the potential ability to modify gluta-
mate receptor activation via the balance between the agonist qui-
nolinic acid and the antagonist kynurenic acid. The high level of
quinolinic acid prenatally which we have reported was also noted
by Cannazza et al., 2001).
A variety of external inﬂuences affect brain development,
including maternal infection or stress (Hornig et al., 1999; Meyer
and Feldon, 2010). The alterations of development are thought to
underlie some neurological or psychiatric disorders in the offspring
(Brown, 2006, 2011; Hornig et al., 1999; Meyer and Feldon, 2010).
Interferons generated during infection, are potent inducers of
indoleamine-2,3-dioxygenase and KMO (Carlin et al., 1989;
Alberati-Giani et al., 1996; Silva et al., 2002; Brooks et al., 2016),
and corticosteroids produced during stress activate TDO (Green and
Fig. 4. Tryptophan metabolism in embryo rat brains. The charts summarise the concentrations of (A) tryptophan, (B) kynurenine, (C) kynurenic acid, (D) 3-hydroxykynurenine, (E)
xanthurenic acid, (F) anthranilic acid and (G) quinolinic acid in the brains of pregnant female rats 24 h after the intraperitoneal administration of Ro61-8048. **P < 0.01 (paired t-
test, n ¼ 6).
Fig. 5. Tryptophan metabolism in the brains of Mecp2þ/ mice. The charts summarise the concentrations of (A) tryptophan, (B) kynurenine, (C) kynurenic acid, (D) 3-
hydroxykynurenine, (E) xanthurenic acid, (F) anthranilic acid and (G) quinolinic acid in the brains of 3e6 week-old Mecp2þ/ mice. No signiﬁcant differences were observed
between the knockdown animals and their normal controls (paired t-test, n ¼ 6).
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1981; Zunszain et al., 2012). These compounds could, therefore,
mediate the effects of infection and stress on kynurenine
metabolism.
Indeed any immune challenge to the mother or neonate which
results, directly or indirectly, in the activation of central glia or
peripheral macrophages, or changes in the levels of cytokines or
kynurenines in the foetal or neonatal CNS, would alter that balance
of concentrations and could seriously perturb neural development
and plasticity (Zavitsanou et al., 2014). This could in turn increase
the risk of CNS disorders, such as schizophrenia, Alzheimer's dis-
ease and Huntington's disease and would be consistent with evi-
dence that genetic abnormalities of the kynurenine pathway are
linked to disorders such as schizophrenia (Holtze et al., 2012;
Sathyasaikumar et al., 2011; Stone and Darlington, 2013). The
blockade of NMDA receptors by kynurenic acid produces neuro-
chemical and behavioural changes which have been likened to
those seen in schizophrenia (du Bois and Huang, 2007; Harris et al.,
2003) and related to altered levels of kynurenic acid in patients as
discussed above.
Overall, the present data strongly support the concept that
constitutive activity of the kynurenine pathway during embryo-
genesis is intimately involved in early brain development. This
conclusion has important implications for the converse possibility
that external factors promoting or suppressing basal activity may
interfere with brain development and, as a result, brain structure
and function in the adult. Infection and stress activate the pathway
and maternal exposure to these factors during pregnancy has been
linked to the emergence of disorders such as schizophrenia in
postnatal life. The kynurenine pathway could be a major contrib-
utor to that association.
4.2. Mecp2þ/ mice
Although Rett syndrome in now recognised and classiﬁed as a
separate disorder, there are features of the syndrome during the
regressive phase that closely resemble phenotypic aspects of ASD.
Several groups have reported links between the kynurenine
pathway and ASD including changes in the KMO gene (McFarlane
et al., 2008) or in the levels of tryptophan, kynurenine, quinolinic
or kynurenic acids in patients with ASD which could account for
some symptoms of the condition via their actions on the nervous or
immune systems (Boccuto et al., 2013; Casanova, 2007; Essa et al.,
2013; McTighe et al., 2013; Schwartz, 2014; Zimmerman et al.,
2005; Lim et al., 2016), while others have failed to ﬁnd a relation-
ship (Sweeten et al., 2006). A study which focussed on Rett syn-
drome concluded that the levels of kynurenine were increased in
striatal regions of the post mortem human brain, whereas seroto-
nin concentrationswere reduced (Riederer et al., 1986). The authors
concluded that the high kynurenine levels could be relevant to the
seizures often experienced by patients with Rett syndrome as a
result of the increased generation of the NMDA receptor agonist
quinolinic acid (Stone and Perkins, 1981; Stone and Darlington,
2002).
The use of female Mecp2þ/ represents an accurate and sex
speciﬁcmodel of Rett syndrome since it is only female childrenwho
develop recognisable symptoms typically survive into adulthood.
The deletion results in far more severe difﬁculties in male children
and is usually lethal in infancy. The absence of changes in trypto-
phan metabolites in the Mecp2þ/ mice might therefore indicate
that changes in tryptophan metabolism along the kynurenine
pathway are not altered in Rett syndrome without seizures. How-
ever, a mouse model with a single selected genetic mutation is not
the same as a human being in which the effects of any genetic
change have been partially compensated by behavioural adaptationor genetic modiﬁers. Disease phenotypes are typically less severe in
mice and their onset more delayed. However, oxidative stress is
known to precede the onset symptoms in mouse models of Rett
syndrome (De Felice et al., 2014) and the fact that we did not
observe signiﬁcant alterations in kynurenine metabolism may
suggest that this pathway is of lesser importance in the patho-
genesis of Rett syndrome. It is also possible that the changes in
kynurenine metabolism that have been described in ASD or Rett
syndrome are secondary to the behavioural abnormalities, reﬂect-
ing the complex physiological and psychological reaction to the
primary cause in humans which would not be expected to be
shared by mice. Viewed overall, the results might indicate that the
reported changes in kynurenine metabolism should be considered
in the category of epi-phenomena possibly related more to the
stress experienced by sufferers of ASD or Rett syndrome or to co-
incident infections and chronic low level inﬂammation.
The observation that kynurenine levels were lower in the wild
type C57BL/6J mice here than in the study of kmo deletion by
Giorgini et al. (2013), whereas anthranilic acid levels were around
10-fold higher, may reﬂect the different genomic background of the
animals since the C57BL/6J mice used for the original conditional
knockouts were subsequently back-crossed at least six times to an
FVBN background, so that genomic features of the latter strain
should predominate. Alternatively, the differences might indicate
represent a gender difference since only female mice were used
here, whereas Giorgini et al. (2013) do not specify gender and
presumably used a mixed population.
In another respect, the use of these mice has served as a control
of the new LC-MSMS system, since intrinsic variability in the
analysis would be predicted to generate some spurious differences
in metabolite concentrations. If the changes in tryptophan meta-
bolism demonstrated above in KMO deﬁcient animals are viewed
as the positive control experiments, the failure to ﬁnd differences
between theMecp2þ/mice and their normal controls can be taken
to support the reliability, reproducibility and robustness of this LC-
MSMS system.
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